Duopharma Biotech Bhd (7148) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Duopharma Biotech Bhd (7148) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM25.12 Million ≈ $6.31 Million USD) by net assets (RM757.35 Million ≈ $190.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Duopharma Biotech Bhd fund operations to measure how many days the company can operate on defensive assets alone.
Duopharma Biotech Bhd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Duopharma Biotech Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Duopharma Biotech Bhd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newron Pharmaceuticals SpA
SW:NWRN
|
0.119x |
|
Zhubo Design
SHE:300564
|
-0.027x |
|
Designer Brands Inc
NYSE:DBI
|
0.147x |
|
Pss Co Ltd
TW:6914
|
0.236x |
|
Fujian Jinsen Forestry Co Ltd
SHE:002679
|
-0.009x |
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
0.027x |
|
Amazing Microelectronic
TWO:6411
|
0.030x |
|
Taiga Building Products Ltd.
TO:TBL
|
-0.173x |
Annual Cash Flow Conversion Efficiency for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Duopharma Biotech Bhd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Duopharma Biotech Bhd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | RM757.62 Million ≈ $190.21 Million |
RM112.71 Million ≈ $28.30 Million |
0.149x | +28.40% |
| 2024-12-31 | RM709.15 Million ≈ $178.04 Million |
RM82.16 Million ≈ $20.63 Million |
0.116x | +54.42% |
| 2023-12-31 | RM687.12 Million ≈ $172.51 Million |
RM51.55 Million ≈ $12.94 Million |
0.075x | -30.04% |
| 2022-12-31 | RM655.22 Million ≈ $164.50 Million |
RM70.27 Million ≈ $17.64 Million |
0.107x | +54.89% |
| 2021-12-31 | RM624.00 Million ≈ $156.67 Million |
RM43.20 Million ≈ $10.85 Million |
0.069x | -37.52% |
| 2020-12-31 | RM643.82 Million ≈ $161.64 Million |
RM71.35 Million ≈ $17.91 Million |
0.111x | -12.32% |
| 2019-12-31 | RM529.75 Million ≈ $133.00 Million |
RM66.96 Million ≈ $16.81 Million |
0.126x | -15.94% |
| 2018-12-31 | RM481.04 Million ≈ $120.77 Million |
RM72.33 Million ≈ $18.16 Million |
0.150x | +28.73% |
| 2017-12-31 | RM479.87 Million ≈ $120.48 Million |
RM56.05 Million ≈ $14.07 Million |
0.117x | +59.71% |
| 2016-12-31 | RM454.52 Million ≈ $114.11 Million |
RM33.24 Million ≈ $8.35 Million |
0.073x | +164.65% |
| 2015-12-31 | RM449.72 Million ≈ $112.91 Million |
RM-50.88 Million ≈ $-12.77 Million |
-0.113x | -160.89% |
| 2014-12-31 | RM193.63 Million ≈ $48.61 Million |
RM35.97 Million ≈ $9.03 Million |
0.186x | -14.16% |
| 2013-12-31 | RM182.65 Million ≈ $45.86 Million |
RM39.53 Million ≈ $9.93 Million |
0.216x | -4.12% |
| 2012-12-31 | RM170.50 Million ≈ $42.81 Million |
RM38.49 Million ≈ $9.66 Million |
0.226x | +91.65% |
| 2011-12-31 | RM164.44 Million ≈ $41.29 Million |
RM19.37 Million ≈ $4.86 Million |
0.118x | -53.56% |
| 2010-12-31 | RM157.87 Million ≈ $39.64 Million |
RM40.04 Million ≈ $10.05 Million |
0.254x | +33.09% |
| 2009-12-31 | RM142.74 Million ≈ $35.84 Million |
RM27.20 Million ≈ $6.83 Million |
0.191x | -5.97% |
| 2008-12-31 | RM130.55 Million ≈ $32.78 Million |
RM26.46 Million ≈ $6.64 Million |
0.203x | -7.77% |
| 2007-12-31 | RM114.21 Million ≈ $28.68 Million |
RM25.10 Million ≈ $6.30 Million |
0.220x | +18.17% |
| 2006-12-31 | RM145.43 Million ≈ $36.51 Million |
RM27.04 Million ≈ $6.79 Million |
0.186x | -- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more